Fifth Third Bancorp Has $785,000 Stock Holdings in Privia Health Group, Inc. $PRVA

Fifth Third Bancorp raised its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 1,047.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,142 shares of the company’s stock after purchasing an additional 34,817 shares during the quarter. Fifth Third Bancorp’s holdings in Privia Health Group were worth $785,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Privia Health Group by 63.5% in the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock valued at $5,514,000 after purchasing an additional 95,371 shares during the period. AQR Capital Management LLC grew its holdings in Privia Health Group by 24.7% during the first quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock worth $916,000 after purchasing an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Privia Health Group by 3.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock worth $2,666,000 after buying an additional 3,714 shares during the last quarter. Intech Investment Management LLC increased its position in Privia Health Group by 55.1% during the first quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock worth $1,270,000 after buying an additional 20,082 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Privia Health Group in the first quarter valued at approximately $154,000. Institutional investors and hedge funds own 94.48% of the company’s stock.

Insider Activity at Privia Health Group

In other news, CFO David Mountcastle sold 21,275 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $27.67, for a total value of $588,679.25. Following the completion of the sale, the chief financial officer owned 164,853 shares of the company’s stock, valued at approximately $4,561,482.51. The trade was a 11.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 15,647 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $22.64, for a total transaction of $354,248.08. Following the completion of the transaction, the chief executive officer owned 434,357 shares in the company, valued at $9,833,842.48. This trade represents a 3.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 478,855 shares of company stock worth $12,099,109 in the last ninety days. 5.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PRVA has been the subject of a number of recent analyst reports. Barclays cut their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 26th. Citigroup restated a “buy” rating on shares of Privia Health Group in a research note on Thursday. Evercore set a $26.00 price target on Privia Health Group in a report on Wednesday, April 8th. Zacks Research downgraded Privia Health Group from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Privia Health Group presently has an average rating of “Moderate Buy” and a consensus target price of $31.15.

Privia Health Group Stock Down 3.3%

Shares of NASDAQ:PRVA opened at $24.67 on Tuesday. Privia Health Group, Inc. has a 12-month low of $18.77 and a 12-month high of $28.82. The business has a 50 day moving average of $24.42 and a 200-day moving average of $23.33. The stock has a market cap of $3.11 billion, a PE ratio of 154.20, a P/E/G ratio of 2.02 and a beta of 0.83.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.